Abstract
Introduction

33
Vulvovaginal candidiasis (VVC) is a common mucosal fungal infection in women 34 of childbearing age (1) . Epidemiology studies where both yeast cultures and symptoms 35 were confirmed (2,3) suggest a prevalence of several million infections in the U.S
36
annually. This prediction is consistent with the estimate of 10 million annual physician 37 visits due to vaginal symptoms and the approximate percentage of about a third of such with a serious impact on quality of life (QOL) (5) . A recent survey determined its QOL 42 index score being equal to that for asthma or COPD and worse than for 43 headache/migraine (6).
44
Pharmaceutical treatments of fungal infections are classified by mechanism of 45 action of a given drug (7). For most mucosal yeast infections such as VVC, the class of 46 choice are the azole antifungal drugs (e.g., fluconazole, itraconazole, clotrimazole, etc.).
47
month prophylaxis, but only to 42% efficacy 6 months after the final dose (10). These 56 data suggest that maintenance fluconazole is largely suppressive in nature, i.e., when 57 therapy is stopped, symptomatic infection returns, and are consistent with relapse being 58 most often due to the same Candida strain (10, 11).
59
In addition to the difficulty in treating recurrent disease, there are indications that 60 drug resistance is increasing, particularly with regard to C. albicans, but also reflects 61 increases of percentages of Candida spp. that are intrinsically less susceptible to 62 antifungal drugs (12). Candida albicans is the predominant yeast species isolated from 63 VVC patients (1) and is inherently sensitive to fluconazole. However, the percentage of 64 non-albicans Candida spp. that are inherently less sensitive to fluconazole (e.g., C. 65 glabrata) may be increasing (13, 14) . Additionally, a higher percentage of non-albicans 66 Candida spp (42%) was measured in RVVC patients than in patients with sporadic 67 infrequent VVC (20%) (15), possibly leading to greater difficulty in treating RVVC due to 68 a higher percentage of species with less susceptibility to azole antifungals.
69
We have recently described a novel fungal CYP51 inhibitor VT-1161 (16) that 70 was designed for greater selectivity relative to off-target human CYP enzymes while 71 retaining the same or greater potency for the fungal CYP51 target (17). 8 μg/ml and a MIC90 of 64 μg/ml) ( Table 1 ). For both sensitive strains and 8 of the 10 158 resistant clinical isolates, the MIC for VT-1161 was equal to or less than 0.015 μg/ml
159
(the lowest concentration tested ) ( Table 1 ). The MICs for the other two fluconazole-
160
resistant clinical isolates were 0.12 and 2 μg/ml. Therefore, the MIC50 and MIC90
161 values were ≤0.015 and 0.12 μg/ml, respectively, which were 500-fold more potent than Table 2 ). VT-1161 was quickly and efficiently absorbed after an oral 
173
The long half-life can be partly explained by two additional observations. VT-174 metabolism after 65 min of incubation with mouse liver microsomes ( Table 2) .
176
Consistent with the long half-life of VT-1161, plasma concentrations accumulated after 177 repeat dosing. For example, in the rat which displays an equally long oral half-life for
178
VT-1161, when dosed once-daily for 7 days, C max and AUC exposures increased 6-7-
179
fold when parameters derived from data taken on the first day were compared with 180 those from the last day of dosing (E.P. Garvey and R.J. Schotzinger, unpublished data). lavage CFUs (7/10 for 4 mg/kg VT-1161, 4/10 for 10 mg/kg VT-1161, 6/10 for 25 mg/kg 197 VT-1161, and 5/9 for fluconazole). The fungal burdens 4 days after treatment showed fungal "rebound" in the low-and mid-dose VT-1161 groups (Table 3; VT-1161 versus 7/10 for high-dose VT-1161 and 7/9 for fluconazole).
208
Concentrations of drug in both plasma and vaginal tissue are also shown in 209   Table 3 . Based on the long half-life of VT-1161 in mice (Table 2) , the high levels of VT- number of clinical isolates from VVC patients that had been tested in vitro (Table 1) 225 were used in a pre-study to confirm infectibility in vivo. All isolates tested established Table 4 . experimental error of each other and of the values determined in the first study using C.
277
albicans 3153A (Table 3 ). This inter-study reproducibility is consistent with the relatively 278 small standard deviations observed within each study, which reflect low inter-animal 279 variability (Table 3 and isolate LP-1158-07 (MIC = 2 and 64 μg/ml for VT-1161 and fluconazole, respectively).
347
The plasma levels of both drugs were very similar in all of these studies with relatively 348 low inter-animal variability, demonstrating reproducibility of their oral pharmacokinetics. 
